DECN Fills in the Gaps, Adds to Knowledge Base for its GenViro Coronavirus (Covid19) Multi-Dimensional Diagnostic Methodology
05 March 2020 - 2:15AM
InvestorsHub NewsWire
DECN Fills in the Gaps, Adds to
Knowledge Base for its GenViro Coronavirus (Covid19)
Multi-Dimensional Diagnostic Methodology
GenViroTM Anticipated
to be Commercial Ready in Summer 2020, Advanced Development Taking
Place at "Ground Zero" in Daegu, Korea, Cost Per Screen Set at
$4.95, Unique Reporting Method to be Used
LOS ANGELES, CA -- March 4, 2020 -- InvestorsHub
NewsWire -- Decision Diagnostics Corp. (OTC
PINK:DECN) is an 18-year old, diabetes-focused bio-technology
development firm, manufacturer, quality plan administrator, FDA
registered medical device customer support organization, and
exclusive worldwide sales and regulatory process agent for the
GenUltimate! ("Sunshine") diabetes test strip, its GenAccord!
systems for the uninsured and under-insured, its GenChoice!
("Ladybug") test strip now in the later stages of FDA 510(k)
prosecution, and its GenUltimate Precis products manufactured for
International markets.
On March 3, 2020, in a break-through discussed then for the
first time, DECN announced the introduction of its new screening
methodology for the Coronavirus (covid19). This innovative, precise
and cost effective product is timely, simple to use, and most
importantly will be commercial ready in the late summer of 2020.
This is the second of a planned three discussions covering the
revolutionary DECN GenViro screening diagnostic for
the Coronavirus (covid19) and other infectious disease
states.
Keith Berman, CEO of DECN commented, "GenViro for the
Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG
product line. What makes the testing for the Coronavirus possible,
and the GenUltimate TBG special, is the company's Impedance
measurement technology.
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
While infectious disease testing and management has not
previously been a part of our business model, we seized on this "do
good" opportunity because our "Gen" line of products are and have
been manufactured since 2016 in what is ground zero for Coronavirus
(covid19) in Daegu, Korea. The company will have available samples
of the blood of those previously infected available for testing as
the company quickly converts its GenUltimate TBG methods and
Precise meter, into a precise infectious disease testing device for
the screening for Coronavirus."
In addition, the company has also just introduced its
GenExpidient! Universal Translator for bio-sensor devices of
different manufacture. Pictured above, this device allows for a
disposable screening method while testing for Coronavirus,
lessening the need to cleanse, disinfect and sanitize the meter
(reading device). With the completion of the company's Precise
meter in late February, there is no need to develop instrumentation
to read the answers from the diagnostic itself. Development of
"hardware" always adds time to a major development project. But not
here.
Mr. Berman concluded, "I again want to reiterate that the
development of our Coronavirus screening method is not a cure or a
vaccine for this virus. That is not to infer that unexpected clever
and useful features are not built into our Coronavirus screening
solution. For example, not only will the screening device provide
the expected NEGATIVE or POSITIVE result (answer), but with each
result provided, the answer will be accompanied by a probability
statistic that will allow the user to determine the probability
that the POSITIVE or NEGATIVE reported by the system may be a false
rendering -- a false POSITIVE or a false NEGATIVE."
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and
worldwide distributor of diabetic test strips engineered to operate
on legacy glucose meters. DECN's products are designed to operate
efficiently and less expensively on certain glucose meters already
in use by almost 7.5 million diabetics worldwide. With new inspired
technology diabetic test strips already in the final stages of
development, DECN products compete on a worldwide scale with legacy
manufacturers currently selling to 71+ percent of a $15+ billion
at-home testing market. The company's GenUltimate TBG product is
not yet available for sale in the United States or Puerto Rico but
is for sale in select International markets since late February
2020.
Forward-Looking Statements:
This release contains the company's forward-looking statements
which are based on management's current expectations and
assumptions as of March 3, 2020, regarding the company's business
and performance, its prospects, current factors, the economy, and
other future conditions and forecasts of future events,
circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
Decision Diagnostics (CE) (USOTC:DECN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Decision Diagnostics (CE) (USOTC:DECN)
Historical Stock Chart
From Nov 2023 to Nov 2024
